HUP0200864A2 - Száraz szem kezelésére szolgáló szer - Google Patents

Száraz szem kezelésére szolgáló szer

Info

Publication number
HUP0200864A2
HUP0200864A2 HU0200864A HUP0200864A HUP0200864A2 HU P0200864 A2 HUP0200864 A2 HU P0200864A2 HU 0200864 A HU0200864 A HU 0200864A HU P0200864 A HUP0200864 A HU P0200864A HU P0200864 A2 HUP0200864 A2 HU P0200864A2
Authority
HU
Hungary
Prior art keywords
treatment
dry eye
macrolide compounds
macrolide
compounds
Prior art date
Application number
HU0200864A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0200864(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of HUP0200864A2 publication Critical patent/HUP0200864A2/hu
Publication of HUP0200864A3 publication Critical patent/HUP0200864A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
HU0200864A 1999-04-30 2000-04-26 Use of macrolide compounds for the treatment of dry eye HUP0200864A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13200999P 1999-04-30 1999-04-30

Publications (2)

Publication Number Publication Date
HUP0200864A2 true HUP0200864A2 (hu) 2002-07-29
HUP0200864A3 HUP0200864A3 (en) 2004-07-28

Family

ID=22452015

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200864A HUP0200864A3 (en) 1999-04-30 2000-04-26 Use of macrolide compounds for the treatment of dry eye

Country Status (23)

Country Link
EP (1) EP1173177B2 (hu)
JP (2) JP5036934B2 (hu)
KR (1) KR20020015316A (hu)
CN (1) CN1190194C (hu)
AR (1) AR023807A1 (hu)
AT (1) ATE281167T1 (hu)
AU (1) AU777915B2 (hu)
BR (1) BR0011225A (hu)
CA (1) CA2372448A1 (hu)
CZ (1) CZ20013769A3 (hu)
DE (1) DE60015516T2 (hu)
ES (1) ES2232439T3 (hu)
HK (2) HK1043321B (hu)
HU (1) HUP0200864A3 (hu)
IL (1) IL146162A0 (hu)
MX (1) MXPA01010988A (hu)
NO (1) NO20015288D0 (hu)
NZ (1) NZ515339A (hu)
PT (1) PT1173177E (hu)
TR (1) TR200103119T2 (hu)
TW (1) TWI230066B (hu)
WO (1) WO2000066122A1 (hu)
ZA (1) ZA200108905B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372448A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
NZ530845A (en) 2001-07-06 2006-03-31 Sucampo Ag Composition for topical administration
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
CA2495103A1 (en) * 2002-08-09 2004-02-19 Sucampo Pharmaceuticals, Inc. Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004062669A1 (en) * 2003-01-16 2004-07-29 Sucampo Ag Use of a macrolide compound for treating dry eye
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US8541468B2 (en) 2003-10-06 2013-09-24 Ophtecs Corporation Ophthalmic composition for treating tear dysfunction
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
JP7278969B2 (ja) * 2017-05-30 2023-05-22 エキシモア・リミテッド ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2066915T3 (es) * 1989-07-05 1995-03-16 Fujisawa Pharmaceutical Co Composicion liquida acuosa para uso externo.
KR100237715B1 (ko) * 1991-04-26 2000-02-01 후지야마 아키라 안과질환에 대한 마크로라이드 화합물의 용도
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JP2002509555A (ja) * 1998-04-06 2002-03-26 藤沢薬品工業株式会社 新規用途
JP3732525B2 (ja) * 1998-04-27 2006-01-05 アステラス製薬株式会社 医薬組成物
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
CA2372448A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye

Also Published As

Publication number Publication date
KR20020015316A (ko) 2002-02-27
CN1190194C (zh) 2005-02-23
DE60015516T2 (de) 2005-12-01
HK1046099A1 (zh) 2002-12-27
NO20015288L (no) 2001-10-29
BR0011225A (pt) 2002-03-19
EP1173177A1 (en) 2002-01-23
HK1043321B (zh) 2005-07-15
IL146162A0 (en) 2002-07-25
AU4142900A (en) 2000-11-17
NZ515339A (en) 2004-02-27
JP5036934B2 (ja) 2012-09-26
ZA200108905B (en) 2002-12-24
PT1173177E (pt) 2005-03-31
ATE281167T1 (de) 2004-11-15
DE60015516D1 (de) 2004-12-09
CN1353608A (zh) 2002-06-12
AR023807A1 (es) 2002-09-04
EP1173177B2 (en) 2014-03-05
NO20015288D0 (no) 2001-10-29
WO2000066122A1 (en) 2000-11-09
EP1173177B1 (en) 2004-11-03
CA2372448A1 (en) 2000-11-09
CZ20013769A3 (cs) 2002-03-13
JP2012116857A (ja) 2012-06-21
JP2002543132A (ja) 2002-12-17
AU777915B2 (en) 2004-11-04
MXPA01010988A (es) 2004-04-21
HUP0200864A3 (en) 2004-07-28
ES2232439T3 (es) 2005-06-01
HK1043321A1 (en) 2002-09-13
TR200103119T2 (tr) 2002-04-22
TWI230066B (en) 2005-04-01

Similar Documents

Publication Publication Date Title
HRP20020253A2 (en) Compounds for the treatment of ischemia
IL196301A0 (en) Medicament for the treatment of hapatitis c
HK1068778A1 (en) Insert for the treatment of dry eye
HUP0200864A3 (en) Use of macrolide compounds for the treatment of dry eye
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB9900150D0 (en) Treatment for fabrics
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL133760A0 (en) Composition for the treatment of dandruff
GB9900151D0 (en) Treatment for fabrics
GB2363604B (en) S-nitrosothiols as agents for the treatment of circulatory dsyfunctions
GB9904252D0 (en) Composition for the treatment of pain
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
GB9919126D0 (en) Glaucoma treatment
GB9925550D0 (en) Glaucoma treatment
GB9903558D0 (en) Medical treatment
GB9908993D0 (en) Treatment
GB9900149D0 (en) Treatment for fabrics
GB9918000D0 (en) Compositions for the treatment of pain
GB9907649D0 (en) Skin treatment
GB9904918D0 (en) Skin treatment
AUPQ282499A0 (en) Treatment of fabric
AU2002328886A1 (en) Insert for the treatment of dry eye
GB9919565D0 (en) Treatment of disease
GB9909650D0 (en) Novel treatment

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees